Daito Pharmaceutical Co., Ltd.September 16, 2022

FDA 483 - Daito Pharmaceutical Co., Ltd. - September 16, 2022

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Daito Pharmaceutical Co., Ltd.

Record Details

An FDA inspection of Daito Pharmaceutical Co., Ltd. in Toyama City, Japan, revealed two observations related to quality system deficiencies. The firm failed to adequately investigate unexplained discrepancies and ensure proper follow-up actions. Additionally, the quality control unit did not fully adhere to its responsibilities and procedures, leading to premature closure of deviation reports and approval of change controls before completion.

Company: Daito Pharmaceutical Co., Ltd.
Inspection Date: September 16, 2022
Product Type: Drugs
Office: Office of Partnerships
Person: Santiago Gallardo Johnson (https://www.fda.gov/media/120628/download)

Open in Dashboard

ID · b83bda10-2781-44c9-afce-1dd89e917c4a